نتایج جستجو برای: tmprss2

تعداد نتایج: 875  

Journal: :Clinical advances in hematology & oncology : H&O 2016
Himisha Beltran

HB NEPC is an aggressive variant of prostate cancer that typically is diagnosed in the later stages of advanced disease. It is thought to arise as a function of treatment resistance.1 In its pure form, NEPC is histologically similar to other high-grade or small cell neuroendocrine carcinomas, often expressing classical neuroendocrine markers (eg, chromogranins) and lacking expression of typical...

2017
Christoph Burdelski Michael Fitzner Claudia Hube-Magg Martina Kluth Asmus Heumann Ronald Simon Till Krech Till Clauditz Franziska Büscheck Stefan Steurer Corinna Wittmer Andrea Hinsch Andreas M. Luebke Frank Jacobsen Sarah Minner Maria Christina Tsourlakis Burkhard Beyer Thomas Steuber Imke Thederan Guido Sauter Jakob Izbicki Thorsten Schlomm Waldemar Wilczak

The A Disintegrin and Metalloproteinase (ADAM) family of endopeptidases plays a role in many solid cancers and includes promising targets for anticancer therapies. Deregulation of ADAM15 has been linked to tumor aggressiveness and cell line studies suggest that ADAM15 overexpression may also be implicated in prostate cancer. To evaluate the impact of ADAM15 expression and its relationship with ...

Journal: :Histology and histopathology 2013
Martin Braun Robert Kirsten Niels J Rupp Holger Moch Falko Fend Nicolas Wernert Glen Kristiansen Sven Perner

Quantification of protein expression based on immunohistochemistry (IHC) is an important step for translational research and clinical routine. Several manual ('eyeballing') scoring systems are used in order to semi-quantify protein expression based on chromogenic intensities and distribution patterns. However, manual scoring systems are time-consuming and subject to significant intra- and inter...

2016
Shan Wang Rahul K. Kollipara Caroline G. Humphries Shi-Hong Ma Ryan Hutchinson Rui Li Javed Siddiqui Scott A. Tomlins Ganesh V. Raj Ralf Kittler

Ets related gene (ERG) is a transcription factor that is overexpressed in 40% of prostate tumors due to a gene fusion between ERG and TMPRSS2. Because ERG functions as a driver of prostate carcinogenesis, understanding the mechanisms that influence its turnover may provide new molecular handles to target the protein. Previously, we found that ERG undergoes ubiquitination and then is deubiquitin...

Journal: :BJU international 2008
David S Morris Scott A Tomlins James E Montie Arul M Chinnaiyan

Chromosomal rearrangements play a causal role in haematological and mesenchymal malignancies. Importantly, the resulting gene fusions can serve as specific therapeutic targets, as exemplified by the development of imatinib (Gleevec), which specifically inhibits the BCR-ABL gene fusion product that defines chronic myeloid leukaemia. Recently, gene fusions involving the prostate-specific gene tra...

Journal: :Endocrine-related cancer 2014
Delila Gasi Tandefelt Joost Boormans Karin Hermans Jan Trapman

Prostate cancer is very common in elderly men in developed countries. Unravelling the molecular and biological processes that contribute to tumor development and progressive growth, including its heterogeneity, is a challenging task. The fusion of the genes ERG and TMPRSS2 is the most frequent genomic alteration in prostate cancer. ERG is an oncogene that encodes a member of the family of ETS t...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2014
Shan Wang Rahul K Kollipara Nishi Srivastava Rui Li Preethi Ravindranathan Elizabeth Hernandez Eva Freeman Caroline G Humphries Payal Kapur Yair Lotan Ladan Fazli Martin E Gleave Stephen R Plymate Ganesh V Raj Jer-Tsong Hsieh Ralf Kittler

The transcription factor E-twenty-six related gene (ERG), which is overexpressed through gene fusion with the androgen-responsive gene transmembrane protease, serine 2 (TMPRSS2) in ∼40% of prostate tumors, is a key driver of prostate carcinogenesis. Ablation of ERG would disrupt a key oncogenic transcriptional circuit and could be a promising therapeutic strategy for prostate cancer treatment. ...

2017
Luca Mologni Vera Magistroni Francesco Casuscelli Marisa Montemartini Carlo Gambacorti-Passerini

PIM1 is over-expressed in multiple tumors, including prostate cancer (PCa). PIM1 upregulation is mediated by direct binding of the ERG transcription factor to its promoter. About 50% of PCa cases are characterized by the presence of the TMPRSS2/ERG fusion, leading to ERG over-expression and thus to PIM1 transcriptional activation. PIM kinases are considered as weak oncogenes, but when combined ...

2014
Lucile Tallon Devillier Luangphakdy Alain Ruffion Marc Colombel Marian Devonec Denis Champetier Philippe Paparel Myriam Decaussin-Petrucci Paul Perrin Virginie Vlaeminck-Guillem

It has been suggested that urinary PCA3 and TMPRSS2:ERG fusion tests and serum PHI correlate to cancer aggressiveness-related pathological criteria at prostatectomy. To evaluate and compare their ability in predicting prostate cancer aggressiveness, PHI and urinary PCA3 and TMPRSS2:ERG (T2) scores were assessed in 154 patients who underwent radical prostatectomy for biopsy-proven prostate cance...

2010
Albert Dobi Bungo Furusato Syed Shaheduzzaman Yongmei Chen Maryanne Vahey Timothy Nydam Isabell A. Sesterhenn David G. McLeod Gyorgy Petrovics Shiv Srivastava

Expression of the ERG proto-oncogene, is activated in 50-70% of prostate tumors by androgen receptor (AR) mediated signals due to the fusion of AR regulated promoters (primarily TMPRSS2 and to a lesser extent SLC45A3 and NDRG1) to the ERG protein coding sequence. Our previous studies of quantitative expression levels of ERG or TMPRSS2-ERG fusion transcripts have noted that relatively low or no ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید